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Identification of a defect in DNA ligase IV in a radiosensitive
leukaemia patient
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The major mechanism for the repair of DNA double-
strand breaks (DSBs) in mammalian cells is
non-homologous end-joining (NHEJ), a process that
involves the DNA-dependent protein kinase [1,2],
XRCC4 and DNA ligase IV [3–6]. Rodent cells and mice
defective in these components are radiation-sensitive
and defective in V(D)J-recombination, showing that
NHEJ also functions to rejoin DSBs introduced during
lymphocyte development [7,8]. 180BR is a radiosensitive
cell line defective in DSB repair, which was derived from
a leukaemia patient who was highly sensitive to
radiotherapy [9–11]. We have identified a mutation
within a highly conserved motif encompassing the active
site in DNA ligase IV from 180BR cells. The mutated
protein is severely compromised in its ability to form a
stable enzyme–adenylate complex, although residual
activity can be detected at high ATP concentrations. Our
results characterize the first patient with a defect in an
NHEJ component and suggest that a significant defect in
NHEJ that leads to pronounced radiosensitivity is
compatible with normal human viability and does not
cause any major immune dysfunction. The defect,
however, may confer a predisposition to leukaemia.
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Results and discussion
To investigate the possibility that 180BR cells might be
defective in NHEJ, we examined the expression and
functions of the known components of the pathway in
both primary 180BR and SV40-transformed 180BR
(180BRneo) cell lines. The three components of the
DNA-dependent protein kinase (DNA-PK) — Ku70,
Ku80 and DNA-PKcs — were expressed at normal levels,
and functional assays showed normal levels of DNA end-
binding and DNA-PK activities (Figure 1) [11]. In con-
trast, the level of XRCC4 was slightly reduced compared
with control primary and immortalised cells (1BR and
1BRneo, respectively) derived from a normal human
fibroblast and, more markedly, the level of DNA ligase IV
was variable and frequently substantially reduced. Follow-
ing changes to the extraction procedure, however, 180BR
cell extracts were obtained with close to normal levels of
XRCC4 and DNA ligase IV (Figure 2a, lanes 1,2), sug-
gesting that XRCC4 or DNA ligase IV might be unusually
sensitive to proteolysis in 180BR cells. 
No differences in the sequences of the XRCC4 cDNA
from 180BRneo and MRC5VI control cells were revealed
by reverse-transcription PCR (RT–PCR). Examination of
the sequence of the DNA ligase IV cDNA from
180BRneo and normal 1BRneo cells by RT–PCR revealed
two polymorphisms or potential errors in the published
sequence (See Supplementary material published with
this article on the internet). More significantly, this analy-
sis identified a G to A mutational change at position 833 of
the DNA ligase IV cDNA in 180BRneo cells compared
with 1BR cells, which results in an arginine-to-histidine
substitution at amino acid position 278 (R278H; see Sup-
plementary material). The same mutational change was
present in the primary 180BR cell line. The mutation
creates an NdeI restriction site, which was shown to be
present in an RT–PCR product from 180BR but not 1BR
cells (see Supplementary material). Finally, the presence
Figure 1
Analysis of 180BR and 1BR cells for the expression of proteins involved
in NHEJ. Whole cell extracts (10 µg of protein) of the indicated cell lines
were loaded onto 6% polyacrylamide gels and analysed by western
blotting using antibodies against DNA ligase IV, Ku80, Ku70 or XRCC4.
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of the mutation was confirmed by sequence analysis of the
full-length DNA ligase IV gene from genomic DNA and
by NdeI digestion of the relevant fragment (see Supple-
mentary material). There was no evidence of a wild-type
allele, suggesting that the patient is homozygous for this
mutation, although the possibility of a single mutated
allele accompanied by a deletion of the other allele has not
been ruled out. This mutation is not a common polymor-
phism, and has not been observed in 200 human DNAs
examined (F. Carlomagno, personal communication).
The R278H mutation lies within the motif KxDGxR
(using the single-letter amino-acid code in which x is any
amino acid), which is conserved between ATP-dependent
DNA ligases and GTP-dependent mRNA-capping
enzymes and includes the predicted active-site lysine (see
Supplementary material) [12–14]. The lysine ε-amino
group in this motif forms a covalent bond with AMP in the
ligase–AMP complex, raising the possibility that 180BR
might be impaired in enzyme–adenylate complex forma-
tion. Using extracts of 1BRneo and 180BRneo cells pre-
pared under defined protein-inhibitor conditions, in which
DNA ligase IV protein levels from 180BRneo cells were
only marginally decreased (Figure 2a, lanes 1,2), the level
of DNA ligase IV in the material immunoprecipitated
using anti-XRCC4 antibodies was similarly only marginally
decreased (Figure 2a, lanes 3–6). Whereas the material
immunoprecipitated from 1BRneo cell extracts by the anti-
XRCC4 antibody yielded an adenylated product with the
size anticipated for the DNA ligase IV–AMP complex, no
protein–adenylate complex was obtained from 180BRneo
cell extracts (Figure 2a). These results show that the defect
in 180BRneo markedly decreases the ability of DNA ligase
IV to form an enzyme–adenylate complex but that the
ligase’s ability to interact with XRCC4 is not impaired.
We next measured the ability of the immunoprecipitated
protein complex from 1BRneo and 180BRneo cell extracts
to ligate a nick in a double-stranded DNA oligonucleotide
for 30 minutes at room temperature. Surprisingly, only
around two-fold less ligase activity was detected in
180BRneo cell extracts compared with extracts from
1BRneo cells, even though no stable enzyme–adenylate
intermediate was detected in the same 180BRneo cell
extracts (Figure 2b). The adenylation and ligation assays
were carried out using markedly different ATP concentra-
tions, however. Because analysis of the 180BR cell extracts
was limited by the decreased stability of the mutant DNA
ligase IV, we used protein expressed in vitro for further
analysis. The R278H mutation was introduced into full-
length DNA ligase IV cDNA and protein–adenylate
complex formation examined using wild-type and mutant
proteins expressed in vitro. The analysis was conducted in
either the absence or presence of XRCC4 (Figure 3a,b). In
both cases, no adenylation activity was detected using the
mutant R278H DNA ligase IV. Adenylation reactions were
carried out using ~0.2 µM ATP whereas the ligation reac-
tions were carried out at 1 mM ATP. When higher ATP
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The R278H mutation impairs DNA ligase IV enzyme activities.
(a) Whole-cell extracts (WCEs; 50 µg protein) of 1BRneo and
180BRneo cells were analysed by western blotting using antibodies
against DNA ligase IV (lanes 1,2). Only slightly reduced levels of DNA
ligase IV were recovered from 180BRneo cells compared with the
results shown in Figure 1, where protease inhibitor cocktail tablets
were not used during extraction. Because DNA ligase IV antibodies
are not efficient in immunoprecipitation (IP), we used anti-XRCC4
antibodies, which efficiently coimmunoprecipitate DNA ligase IV [4],
to extract DNA ligase IV from WCEs (6 mg). DNA ligase IV exists
endogenously as an enzyme–adenylate complex; we therefore
examined DNA ligase IV–adenylate formation either with or without
previous treatment with 5 mM inorganic pyrophosphate (+ or – PPi,
respectively) for 15 min. PPi disrupts preformed AMP–ligase
complexes [5,21]. One tenth of each sample was examined by western
blotting (lanes 3–6) and the remainder was used for an assay of
adenylation. DNA ligase I was not detectable by western blotting.
(b) WCE (2.5 mg protein) of 1BRneo or 180BRneo cells was
immunoprecipitated using anti-XRCC4 antibodies and the
immunoprecipitated material treated with PPi as described above and
then examined for ligase activity. In other experiments the PPi treatment
was omitted and identical ligation was observed. The ligation products
were separated by 12% denaturing PAGE. The sizes of the single-
stranded oligonucleotides are as indicated. The 33mer was
radiolabelled and ligation produced a radiolabelled 50mer product. The
immunoprecipitated material gave an adenylation product from
1BRneo but not 180BRneo cell extracts similar to that shown in
Figure 2a. The immunoprecipitated material from both cell lines had
similar levels of DNA ligase IV, as assessed by western blotting (data
not shown).
concentrations were used in the adenylation reaction, low
but residual adenylation activity could be detected using
the R278H mutant protein (Figure 3c). Thus, the 180BR
mutation severely inhibits, but does not abolish, the ability
of DNA ligase IV to form an enzyme–adenylate intermedi-
ate. As found with the cell-free extracts, the mutation does
not inhibit interaction with XRCC4. 
It has not been possible so far to derive immortalised
180BR cells. The impact of the R278H mutation on DNA
ligase IV activity in vivo was therefore investigated using
S. cerevisiae as a model organism, because yeast ligase IV
(Lig4p or Dnl4p) is known to function in NHEJ [15–17].
No detectable stable DNA ligase IV–adenylate complex
was observed in a yeast lig4 deletion strain expressing the
corresponding R278H mutation (yeast R287H), in contrast
to cells expressing wild-type Lig4p (Figure 4a). The
mutation had no impact on the interaction of Lig4p with
the yeast XRCC4 homologue Lif1p (data not shown) [18].
Using an in vivo plasmid-rejoining assay, NHEJ was
shown to be impaired but not abrogated in cells express-
ing the R287H mutant protein (Figure 4b). In contrast,
mutation of Arg287 to alanine (R287A) or mutation of the
active-site lysine residue Lys282 to alanine (K282A) dra-
matically reduced NHEJ (Figure 4b). Although deletion
of lig4 does not sensitise the yeast strains to radiation,
rad52/lig4 double mutants show elevated radiosensitivity
compared with rad52 single mutants [16,17]. Expression
of wild-type Lig4p complements the radiosensitivity
defect of the lig4 disruption in the rad52 background,
whereas expression of the R287H mutant protein does not
fully complement the defect (Figure 4c). These data show
that Lig4p bearing the R287H mutation is impaired, but
not completely defective, in its DSB-rejoining function
and provide strong evidence that this mutation is responsi-
ble for the radiosensitivity of 180BR cells. 
These findings confirm a role for DNA ligase IV in DSB
repair in mammalian cells, and identify LIG4 as one of the
few characterised genes, in addition to ATM, NBS1 and pos-
sibly BRCA1 and BRCA2, that contribute to human
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Figure 3
Examination of mutant and wild-type DNA ligase IV expressed in vitro. 
(a) Amino-terminally histidine (His)-tagged mutant (R278H) and wild-type
(WT) DNA ligase IV was expressed in a rabbit reticulocyte lysate as
described in Materials and methods. Expressed protein was
immunoprecipitated using an anti-His antibody and immunoprecipitates
were examined for DNA ligase IV expression by western blotting using an
antibody against DNA ligase IV (upper panel) and by an adenylation
assay (lower panel). (b) His- and S-tagged mutant and wild-type DNA
ligase IV were coexpressed with His-tagged XRCC4 in bacteria. In the
absence of coexpressed XRCC4 little soluble DNA ligase IV protein was
synthesised. DNA ligase IV–XRCC4 complexes were recovered using
S-protein agarose and analysed by Coomassie blue staining or used in
an adenylation assay. Similar results were obtained when ligase IV and
XRCC4 were purified by Ni–NTA agarose chromatography (data not
shown). Western blot analysis confirmed the recovery of these proteins
(data not shown). (c) The His-tag-purified, coexpressed ligase
IV–XRCC4 complex was used in adenylation assays in the presence of
either 0.2, 2 or 20 µM ATP. Samples were resolved by SDS–PAGE and,
after transfer to nitrocellulose, filters were probed with an antibody
against DNA ligase IV to confirm that equal levels of DNA ligase IV had
been used in each assay. Adenylated proteins were detected by
phosphorimager analysis of the same filter used in western blot analysis.
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Figure 4
Examination of yeast cells expressing the corresponding R278H
mutation. (a) Yeast whole cell extracts prepared from strains expressing
wild-type (WT, lane 1) or mutated haemagglutinin (HA)-tagged Lig4p
under the control of the GAL1-10 promoter (lanes 2–4) and FLAG-
tagged Lif1p were used in immunoprecipitations using anti-FLAG
antibodies. One tenth of the immunoprecipitate was subjected to
western blot analysis using anti-HA antibodies to detect the presence of
Lig4p (upper gel) and the remainder was incubated with [α-32P]ATP to
form an enzyme–adenylate complex that was detected by
autoradiography (lower gel). (b) The results of five independent plasmid-
repair assays performed using lig4 mutant strains bearing a plasmid that
contains either the full-length wild-type LIG4 gene or the indicated LIG4
mutant genes are shown. Similar results were obtained when Lig4p was
expressed under the control of the GAL1-10 promoter (data not shown).
(c) The susceptibility of various yeast strains to killing by ionising radiation
was judged by survival after exposure to various radiation doses. Mutant
rad52/lig4 strains were transformed with pRS416 containing the full-
length LIG4 wild-type or R278H mutant genes, and the resultant strains
were tested for survival after various doses of ionising radiation. Error
bars represent the mean ± standard deviation of five experiments. Where
not visible error bars are smaller than the symbols. 
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radiosensitivity [6,8]. Despite displaying pronounced radia-
tion sensitivity, 180BR cells are not significantly defective
in V(D)J recombination and the patient did not display
overt immunodeficiency [9,11]. The most likely explana-
tion for this is that the residual DNA ligase IV activity in
180BR cells is sufficient for V(D)J recombination and for its
reported essential role(s) [8,19] but does not suffice for effi-
cient repair of radiation-induced DSBs, for which abundant
activity may be required. These findings have important
implications for the impact of defects in NHEJ on human
health, as they show that defects conferring significant
radiosensitivity need not be associated with immune dys-
function. Finally, the patient from whom 180BR cells were
derived developed acute lymphoblastic leukaemia at age 14
[9]. Pronounced radiosensitivity is rare among leukaemia
patients and major defects in NHEJ components are
unlikely to contribute significantly to the incidence of
leukaemia. Nevertheless, it is possible that minor defects in
NHEJ confer mild radiosensitivity and a predisposition to
leukaemia, and that these could contribute significantly to
the incidence of leukaemia in the general population. Our
data also raise the possibility that variations in NHEJ might
contribute to the variation between patients in their clinical
radiosensitivity, a major obstacle in optimising radiotherapy.
Materials and methods
Immunoblotting, adenylation and ligation 
Whole cell extracts were prepared by the method of Scholer et al. [20].
The anti-XRCC4 antibody, SJ4A, was raised against full-length XRCC4
protein [4]; the anti-DNA ligase IV antibody was raised against carboxy-
terminal residues 550–844 of DNA ligase IV. DNA ligase IV from whole
cell extracts was immunopurified using anti-XRCC4 antibodies. The
immunoprecipitate was resuspended in adenylation buffer (see Supple-
mentary materials) and adenylation was carried out with 10 µCi [α-
32P]ATP (800 Ci/mmol) at room temperature for 15 min, or with
concentrations of ATP as stated [5]. For ligation, 1 mM ATP was added
to the resuspended proteins together with the substrate, a radiola-
belled 33mer plus an unlabelled 17mer annealed to a complementary
50mer to create a nicked double-stranded oligonucleotide [5].
Expression of recombinant DNA ligase IV
For the in vitro transcription–translation system, amino-terminally His-
tagged DNA ligase IV cDNA was subcloned in-frame into the mam-
malian expression vector pcDNA3 (Invitrogen) and expressed using
Promega TNT T7 Quick Coupled Transcription/Translation System. For
the bacterial expression system, DNA ligase IV cDNA was cloned in-
frame downstream of the His- and S-tag of pET30 (Novagen). DNA
ligase IV and XRCC4 were coexpressed in bacterial cells and purified
using the His and S tags.
Yeast mutagenesis, strains and assays
The lig4 mutant strain, plasmid repair assays and survival analysis were
carried out as described previously [16].
Supplementary material
Additional methodological details are published with this paper on the
internet.
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Supplementary materials and methods
Cell culture
180BRneo is an SV40-transformed but not immortalised cell line
derived from the 180BR primary human fibroblast line [S1]. 1BR3 is a
normal primary fibroblast line; 1BRneo and MRC5VI are two SV40-
immortalised human fibroblast lines, which were used as controls. Cells
were cultured in Minimum Essential Medium (MEM) supplemented with
15% foetal calf serum (FCS), penicillin and streptomycin, as described
previously [S2].
Immunoblotting
In initial experiments, whole cell extracts were prepared by the method
of Scholer et al. [S3]. In later experiments, which gave stable DNA
ligase IV, the protease inhibitors were replaced with protease inhibitor
cocktail tablets (Boehringer Mannheim). For immunoblotting, whole cell
extracts were boiled in SDS–PAGE loading buffer, separated on 6%
polyacrylamide gels and the proteins transferred to nitrocellulose using
a wet-blotting apparatus.  The Ku primary antibodies utilised were
Ku80-4 and N3H10, raised against baculovirus-expressed Ku80 and
Ku70 proteins, respectively (Serotec). The anti-XRCC4 antibody,
SJ4A, was raised against full-length XRCC4 protein, as described pre-
viously [S4]. The antibody against DNA ligase IV was raised against a
peptide comprising the carboxy-terminal residues 550 to 844 of DNA
ligase IV inserted in-frame downstream of the hexahistidine (His6) tag
of pQE-30 (Qiagen). Filters were developed using an enhanced chemi-
luminescence (ECL) kit (Amersham). 
Adenylation and ligation assays
DNA ligase IV from whole cell extracts was immunopurified by coim-
munoprecipitation with anti-XRCC4 antibodies using universal buffer
(50 mM Tris–HCl pH 7.5, 150 mM NaCl, 2 mM EDTA, 2 mM EGTA,
25 mM NaF, 25 mM β-glycerolphosphate, 0.1 mM sodium orthovanadate
and protease inhibitor cocktail tablets). Immunoprecipitates were bound
to protein-A–Sepharose beads (Sigma), washed twice with universal
protease buffer containing 1 M NaCl, treated with 5 mM pyrophosphate
and fresh protease inhibitors for 15 min at RT in the samples indicated,
and then washed once with adenylation buffer (60 mM Tris–HCl pH 8.0,
10 mM MgCl2, 5 mM DTT, 50 µg/ml purified bovine serum albumin
(BSA)). Samples were then used in western blotting or in adenylation
and ligation assays, as described previously [S5]. Briefly, the immunopre-
cipated protein was resuspended in adenylation buffer plus protease
inhibitors, and adenylation carried out with 10 µCi [α-32P]ATP
(800 Ci/mmol), or various other concentrations of ATP, at room tempera-
ture for 15 min. Samples were boiled in SDS–PAGE loading buffer and
run on 6% polyacrylamide gels, fixed for 10 min in 10% acetic acid and
dried, before exposure. For ligation, 1 mM ATP was added to the resus-
pended proteins together with the substrate. The substrate used was a
radiolabelled 33mer plus an unlabeled 17mer annealed to a complemen-
tary 50mer, creating a nicked, double-stranded oligonucleotide. Ligation
produces a radiolabelled 50mer. The sequence of the primers used are:
50mer, 5′GGGTGGATTCGTCCGCTGGAACCTTCCTTCCCTCCC-
CTCGTCTAGATCCC; 17mer, 5′AGCGGACGAATCCACCC; 33mer,
5′GGGATCTAGACGAGGGGAGGGAAGGAAGGTTCC. Ligation was
carried out at room temperature for 30 min. The samples were heated at
80°C in formamide-gel loading buffer for 3 min and run on a 12% dena-
turing polyacrylamide gel. 
Synthesis and sequencing of cDNA 
Total RNA was extracted from 3 × 106 cells using a purification kit
involving Trizol Reagent (Life Technologies). A First Strand cDNA syn-
thesis kit (Amersham Pharmacia Biotech) was used to synthesise
cDNA. DNA ligase IV cDNA was amplified by RT–PCR and directly
sequenced using the Thermo Sequenase 33P-Radiolabeled Terminator
Cycle Sequencing Kit (Amersham Life Science). XRCC4 cDNA was
amplified by RT–PCR, the products cloned into pGEM-T (Promega)
and analysed by automated DNA sequencing. Both strands of three
clones were sequenced for XRCC4 from control and 180BR cells.
Supplementary material
Figure S1
Analysis of 180BR and 1BR cells for the
expression of proteins involved in NHEJ. 
(a) Two changes were present in DNA ligase
IV from both cell lines compared with the
published sequence (C→T and G→C at
positions 737 and 1816, respectively). These
probably represent polymorphisms or errors in
the published sequence. The more significant
mutation (G→A at position 833) was present
only in 180BR cells and is indicated by an
arrow. The non-mutated nucleotide in 1BR
cells is indicated by an arrowhead. (b) A
fragment of 487 base pairs (bp) from DNA
ligase IV DNA encompassing the mutational
change was amplified using cDNA and
genomic DNA from 180BR and 1BR cells.
The mutation creates an NdeI restriction site
and NdeI cleavage was predicted to generate
fragments of 450 and 37 bp. The products
generated without restriction digestion or
following digestion with NdeI were separated
by 2% agarose gel electrophoresis. The PCR
products from 1BR cells were not cleaved by
NdeI digestion, in contrast to the 180BR
products derived from both cDNA and
genomic DNA. The 37 bp fragment was not
recovered but the anticipated 450 bp product
is evident. (c) Conservation of motif I between
DNA ligases and mRNA capping enzymes.
Hs, Homo sapiens; Sc, Saccharomyces
cerevisiae; T7, bacteriophage T7; PBCV CE,
Chlorella virus capping enzyme.
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Expression of recombinant DNA ligase IV
For the in vitro transcription/translation system, amino-terminally His-
tagged DNA ligase IV cDNA was subcloned in-frame into the mam-
malian expression vector pcDNA3 (Invitrogen). The R278H mutation
was introduced by site-directed mutagenesis using the QuickChange
TmSite-directed Mutagenesis Kit (Stratagene). The presence of the
mutation was verified by DNA sequencing and restriction digestion.
The wild-type and mutant constructs (2 µg of each) were expressed in
50 µl transcription/translation system buffer following the manufactur-
er’s instructions (Promega TNT T7 Quick Coupled Transcription/Trans-
lation System). DNA ligase IV was affinity purified using an anti-His
antibody (Clontech). The affinity-purified protein from three transcrip-
tion/translation reactions was utilised for a combined experiment involv-
ing western blotting and an adenylation assay.
For the bacterial expression system, DNA ligase IV cDNA was cloned
in-frame downstream of the His tag and S tag of pET30 (Novagen).
The R278H mutation was introduced by swapping an NheI/DraIII
restriction fragment of DNA ligase IV with the same fragment amplified
from 180BR cells by RT–PCR. The presence of the mutation was con-
firmed by sequence analysis. The amino-terminal 213 residues of
XRCC4 were cloned in-frame downstream of the His6 tag of pET15b
(Novagen). DNA ligase IV and XRCC4 were co-expressed in bacterial
cells and purified using the His and S tags.
Yeast mutagenesis, strains and assays
Mutation of residues Lys282 and Arg287 to alanine, and Arg287 to
histidine were performed using the Stratagene QuikChange Kit using
as template either the full-length LIG4 gene cloned in pRS416 or the
LIG4 ORF (with an amino-terminal His6 and HA2 tag) under the control
of the GAL1-10 promoter cloned into pRS304. The non-mutated or
mutated plasmids were transformed into W303a (pRS304-derived
plasmids) or lig4 mutant (pRS416-derived plasmids) strains, respec-
tively. The LIF1 open-reading frame was cloned (with an amino-terminal
His8 and FLAG tag) under the control of the GAL1-10 promoter in
pRS306 and transformed into strains expressing either tagged wild-
type or mutated LIG4p. Plasmid repair assays were performed as
described previously using the plasmid pRS415 digested with XbaI
[S6]. Immunoprecipitations were performed using whole cell extracts
with either anti-HA antibodies (3F10; Boehringer Mannheim) or anti-
FLAG antibodies (Sigma) in buffer containing 20 mM HEPES pH 7.5,
2 mM MgCl2, 2 mM EDTA, 20% glycerol, 0.5% NP40 and 1 M NaCl.
Immunoprecipitations were performed in strains expressing both
tagged Lig4p and Lif1p.
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